Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases

A technology for acute kidney injury and metformin, which can be used in drug combinations, urinary system diseases, etc., and can solve problems such as metformin yet

Inactive Publication Date: 2015-12-09
无锡翰邦咨询策划有限公司
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report that metformin can protect against cisplatin-induced acute kidney injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases
  • Application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases
  • Application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 2

[0028] Example 1 Effect of metformin on renal function in cisplatin-induced acute kidney injury.

[0029] Male CD1 mice with a body weight of 20-25 g were taken, 6-12 in each group, namely the equal volume normal saline group, the metformin alone group, the cisplatin model group and the metformin treatment group. in,

[0030] Equal volume of normal saline group: intraperitoneal injection, 10ml / kg, once a day, a total of 5 days;

[0031] Simple metformin group: intraperitoneal injection, 100mg / kg, once a day, 5 times in total;

[0032] Cisplatin model group: intraperitoneal injection, 20mg / kg, single administration;

[0033] Metformin treatment group: Metformin was administered three days in advance, intraperitoneal injection, 100mg / kg, once a day, followed by a single administration of cisplatin (intraperitoneal injection, 20mg / kg), metformin was treated for another two days, 48 ​​hours after cisplatin injection , the eyeballs were picked to take blood, and the kidney tissu...

Embodiment 2

[0036] Example 2 Effect of metformin on cisplatin-induced tubular cell apoptosis.

[0037] TUNEL (TdT-mediateddUTPNick-EndLabeling) and cleaved-caspase3 positive renal tubular apoptotic cells were detected by tissue immunofluorescence.

[0038] The result is as figure 2 As shown, there were no obvious CleavedCaspase3 positive cells under the microscope in the normal saline group and the metformin group alone, there were 6.313±0.5995 positive cells in each high-power field in the cisplatin group, and there were 3.533±0.9366 positive cells in each high-power field in the metformin treatment group Positive cells (n=5). There were no obvious Tunel-positive cells under the microscope in the normal saline group and the metformin group alone, but there were 6.411±0.50 positive cells in each high-power field in the cisplatin group, and 3.35±0.6813 positive cells in each high-power field in the metformin treatment group (n= 5). It can be seen from the results that there are few apo...

Embodiment 3

[0039] Example 3 Effect of metformin on cisplatin-induced renal inflammatory cell infiltration.

[0040] The infiltration of inflammatory cells in the kidney was determined by immunofluorescence staining to detect the expression level of F4 / 80 (macrophage marker) and immunohistochemical staining to detect the expression level of Ly6b (neutrophil marker).

[0041] The result is as image 3 As shown, there were no obvious F4 / 80 positive cells under the microscope in the normal saline group and the metformin group alone. There were 5.483±0.3838 positive cells per high-power field in the cisplatin group, and 1.858±0.1425 positive cells in each high-power field in the metformin treatment group. Positive cells (n=5); there were no obvious Ly6B positive cells under the microscope in the normal saline group and the metformin group, there were 5.800±1.659 positive cells in each high-power field in the cisplatin group, and there were 1.433 positive cells in each high-power field in the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases, and discloses application of melbine in new indication. The melbine disclosed by the invention can be used for relieving cisplatin-induced acute kidney injury related diseases which include acute kidney injury renal function, apoptosis of renal tubular cell, renal inflammatory cell infiltration and like diseases; and acute kidney injury is relieved by inhibiting the apoptosis of renal tubular cell mainly by improving the autophagy level of the renal tubular cell.

Description

technical field [0001] The present invention relates to a new use of metformin, in particular to the use of metformin in the preparation of medicines for alleviating cisplatin-induced acute kidney injury-related diseases. Background technique [0002] Acute kidney injury (acute kidney injury, AKI) refers to the sudden decline in renal function, which may or may not be accompanied by oliguria or anuria. It is a clinical syndrome in which renal function is sharply decreased or lost in a short period of time caused by glomerulus, renal tubule, renal interstitium or vascular disease. Symptoms such as hypothermia, water and electrolyte disturbance, and metabolic acidosis. The prevalence of AKI was 1% in the community and 7.1% in the hospital. The morbidity rate is 10% to 80% for AKI acquired in the hospital every year, the fatality rate for multiple organ failure is >50%, and the fatality rate for renal replacement therapy is 80%, so acute kidney injury has a high morbidity ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/155A61P13/12
Inventor 戴春笋李建中谈津
Owner 无锡翰邦咨询策划有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com